97 related articles for article (PubMed ID: 24374007)
1. The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator.
Brandish PE; Anderson K; Baltus GA; Bai C; Bungard CJ; Bunting P; Byford A; Chiu CS; Cicmil M; Corcoran H; Euler D; Fisher JE; Gambone C; Hasbun-Manning M; Kuklin N; Landis E; Lifsted TQ; McElwee-Witmer S; McIntosh IS; Meissner RS; Miao J; Mitchell HJ; Musselman A; Schmidt A; Shin J; Szczerba P; Thompson CD; Tribouley C; Vogel RL; Warrier S; Hershey JC
Eur J Pharmacol; 2014 Feb; 724():102-11. PubMed ID: 24374007
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines.
Ulmansky R; Turjeman K; Baru M; Katzavian G; Harel M; Sigal A; Naparstek Y; Barenholz Y
J Control Release; 2012 Jun; 160(2):299-305. PubMed ID: 22226777
[TBL] [Abstract][Full Text] [Related]
5. LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo.
López FJ; Ardecky RJ; Bebo B; Benbatoul K; De Grandpre L; Liu S; Leibowitz MD; Marschke K; Rosen J; Rungta D; Viveros HO; Yen WC; Zhi L; Negro-Vilar A; Miner JN
Endocrinology; 2008 May; 149(5):2080-9. PubMed ID: 18218700
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid receptor modulators informed by crystallography lead to a new rationale for receptor selectivity, function, and implications for structure-based design.
Carson MW; Luz JG; Suen C; Montrose C; Zink R; Ruan X; Cheng C; Cole H; Adrian MD; Kohlman DT; Mabry T; Snyder N; Condon B; Maletic M; Clawson D; Pustilnik A; Coghlan MJ
J Med Chem; 2014 Feb; 57(3):849-60. PubMed ID: 24446728
[TBL] [Abstract][Full Text] [Related]
7. Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.
Gabrielsson J; Hjorth S; Vogg B; Harlfinger S; Gutierrez PM; Peletier L; Pehrson R; Davidsson P
Eur J Pharm Sci; 2015 Jan; 67():144-159. PubMed ID: 25435491
[TBL] [Abstract][Full Text] [Related]
8. Discovery of selective glucocorticoid receptor modulator MK-5932.
Bungard CJ; Hartman GD; Manikowski JJ; Perkins JJ; Bai C; Brandish PE; Euler DH; Hershey JC; Schmidt A; Fang Y; Norcross RT; Rushmore TH; Thompson CD; Meissner RS
Bioorg Med Chem; 2011 Dec; 19(24):7374-86. PubMed ID: 22079253
[TBL] [Abstract][Full Text] [Related]
9. Azaxanthene based selective glucocorticoid receptor modulators: design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4-thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS-791826).
Weinstein DS; Gong H; Doweyko AM; Cunningham M; Habte S; Wang JH; Holloway DA; Burke C; Gao L; Guarino V; Carman J; Somerville JE; Shuster D; Salter-Cid L; Dodd JH; Nadler SG; Barrish JC
J Med Chem; 2011 Oct; 54(20):7318-33. PubMed ID: 21899328
[TBL] [Abstract][Full Text] [Related]
10. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
Harris RR; Black L; Surapaneni S; Kolasa T; Majest S; Namovic MT; Grayson G; Komater V; Wilcox D; King L; Marsh K; Jarvis MF; Nuss M; Nellans H; Pruesser L; Reinhart GA; Cox B; Jacobson P; Stewart A; Coghlan M; Carter G; Bell RL
J Pharmacol Exp Ther; 2004 Dec; 311(3):904-12. PubMed ID: 15277581
[TBL] [Abstract][Full Text] [Related]
11. Selective glucocorticoid receptor modulation inhibits cytokine responses in a canine model of mild endotoxemia.
Bartko J; Derhaschnig U; Neels T; Nabozny GH; Harcken C; Leuschner J; De Vries F; Jilma B
Pharmacol Res; 2017 Nov; 125(Pt B):215-223. PubMed ID: 28923543
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
Qian M; Bai SA; Brogdon B; Wu JT; Liu RQ; Covington MB; Vaddi K; Newton RC; Fossler MJ; Garner CE; Deng Y; Maduskuie T; Trzaskos J; Duan JJ; Decicco CP; Christ DD
Drug Metab Dispos; 2007 Oct; 35(10):1916-25. PubMed ID: 17656469
[TBL] [Abstract][Full Text] [Related]
13. Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessment of IkappaB kinase-2 (IKK-2) target safety and efficacy.
Chiang PC; Kishore NN; Thompson DC
J Pharm Sci; 2010 Mar; 99(3):1278-87. PubMed ID: 19743500
[TBL] [Abstract][Full Text] [Related]
14. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
15. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram.
Buttini M; Mir A; Appel K; Wiederhold KH; Limonta S; Gebicke-Haerter PJ; Boddeke HW
Br J Pharmacol; 1997 Dec; 122(7):1483-9. PubMed ID: 9421299
[TBL] [Abstract][Full Text] [Related]
16. 5-Functionalized indazoles as glucocorticoid receptor agonists.
Bai M; Carr G; Deorazio RJ; Friedrich TD; Dobritsa S; Fitzpatrick K; Guzzo PR; Kitchen DB; Lynch MA; Peace D; Sajad M; Usyatinsky A; Wolf MA
Bioorg Med Chem Lett; 2010 May; 20(10):3017-20. PubMed ID: 20427184
[TBL] [Abstract][Full Text] [Related]
17. JTP-117968, a novel selective glucocorticoid receptor modulator, exhibits significant anti-inflammatory effect while maintaining bone mineral density in mice.
Kurimoto T; Tamai I; Nakagawa T; Miyai A; Yamamoto Y; Kosugi Y; Deai K; Hata T; Ohta T; Matsushita M; Yamada T
Eur J Pharmacol; 2021 Mar; 895():173880. PubMed ID: 33476654
[TBL] [Abstract][Full Text] [Related]
18. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis.
Magari K; Miyata S; Nishigaki F; Ohkubo Y; Mutoh S; Goto T
J Rheumatol; 2003 Oct; 30(10):2193-200. PubMed ID: 14528517
[TBL] [Abstract][Full Text] [Related]
20. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases.
Kato M; Hagiwara Y; Oda T; Imamura-Takai M; Aono H; Nakamura M
J Ocul Pharmacol Ther; 2011 Aug; 27(4):353-60. PubMed ID: 21574866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
